REG - GenIP PLC Tekcapital plc - Commercial Strategy Update & New Products

TekcapitalAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250930:nRSd2387Ba&default-theme=true

RNS Number : 2387B  GenIP PLC  30 September 2025

 

 

30 September 2025

 

GenIP Plc

("GenIP" or the "Company")

 

Commercial Strategy Update & New Products

 

Launching additional product lines as an AI-powered, platform-led consultancy

 

GenIP Plc, a technology consultancy providing Generative Artificial
Intelligence (GenAI) services to help research organisations and corporations
commercialise their innovations, is pleased to issue an update on its products
and commercial strategy.

 

Building on the foundations of GenIP's first year since incorporation, the
Company is transitioning from project-based service provider to a scalable
AI-powered innovation platform, positioning for accelerated revenue growth and
market penetration.

 

Brand consolidation, platform unity and team expansion

GenIP is consolidating its brand architecture by bringing Invention Evaluator
and Talent Search (Vortechs) under a unified platform identity (GenIP.ai).
This strategic move creates clear service tiers and integrated cross-selling
opportunities for clients.

Invention Evaluator name and brand remain the flagship product, leveraging its
strong market recognition and clear value proposition. Vortechs is being
re-branded as GenIP Talent and Executive Search Services.

This consolidation strengthens brand equity while simplifying the client
experience across all touchpoints.

Andrea Quiros has joined the Company to lead GenIP Talent and Executive search
services. Andrea Quiros brings a wealth of experience in technical talent
acquisition, having led and supported recruitment initiatives for global
innovation leaders, including IBM, Palo Alto Networks, and Amazon in Central
America.

Our brand consolidation, platform unity, and team expansion reflects GenIP's
broader strategy to become the go-to partner for innovation triage and
execution, offering a full-spectrum capability that spans GenAI-powered
analysis, strategic talent acquisition, and venture-ready operational support.

 

Evolution to an AI-Powered, platform-led consultancy

 

The evolution to a platform-led client engagement model lays the foundation
for:

 

●     Recurring SaaS-style revenues from platform-delivered services.

●     Margin expansion via automation and data re-use.

●     Defensible IP and data assets that strengthen long-term strategic
position.

 

New Product Launches

 

The Company plans to launch a suite of new products and services that will
expand GenIP's AI powered offering and evolve it into a more complete
innovation platform. All new product lines are being powered by the highly
automated Invention Evaluator platform and workflow. The consulting services
are being automated through internal dashboards that streamline analysis and
enable human consultants to focus on delivering strategic oversight. This
ensures consistency, efficiency, and strong margins, with added value layered
on top of a proven base report.

 

These new product offerings are designed to deepen relationships with our
existing client base, and create high-margin consulting pathways as add-on
services to the current entry-level Invention Evaluator report. Each add-on
leverages the insights from our reports to expand into advisory, monetization,
and commercialization services:

 

●    Invention Prioritiser - Systematically rank technology portfolios by
different criteria, including technical merit, market potential, IP strength,
and commercialization readiness. This helps clients decision making when
allocating resources to ensure the inventions and technologies with the
highest probability of impact are prioritised and de-risking decisions on
weaker IP.

 

●    Invention Validator: Market Validation & Buyer Perception
Studies - Beyond market sizing, these services design and run targeted
questionnaires and stakeholder interviews to test assumptions, measure buyer
interest, evaluate pricing sensitivity, and assess packaging/positioning-
turning raw research into actionable market intelligence.

 

●     Venture & Partner Intelligence - Identify, map, and validate
potential collaboration or acquisition targets, providing clients with a
curated pipeline of industry partners, venture investors, and licensees
aligned with their portfolio.

●     Innovation Boost - A visibility kit for technologies, including
targeted materials, pitch decks, and warm introductions to industry contacts
to accelerate deal flow and licensing opportunities.

●    Training & Capability Building - Practical, modular programs
covering commercialization best practices, IP strategy, and partnership
development. These sessions strengthen client teams and embed GenIP as a
long-term strategic partner. These services, when combined, can be used to
structure or scale a Technology Transfer Office (TTO).

 

●    Commercialisation Readiness Audits - Assess the readiness of
university departments, science park tenants, or incubator cohorts to
commercialize their innovations using Invention Evaluator reports as the
foundation. Each audit delivers a clear, evidence-based roadmap of next steps,
strengthened by a layer of human experts who interpret and prioritize the
findings.

 

●    Portfolio Monetisation Strategy - Tailored strategies to unlock
revenue pathways for universities and research organizations, built directly
on the findings of Invention Evaluator reports. We identify high-potential
assets and shape practical routes, licensing models, spin-out creation, and
partnership structures, with added depth from a human expert layer that
ensures relevance and actionability.

●    Royalty & Licensing Benchmark - Provide deal-term benchmarks
drawn from comparable transactions, enabling universities, corporates, and
investors to negotiate from a position of strength.

 

 

Melissa Cruz, CEO of GenIP, commented:

 

"GenIP is entering its next phase of growth as an AI-powered, platform-led
consultancy. By unifying our brand and expanding our product suite, we are
creating a high-growth model that turns one-off projects into long-term client
relationships. This is about more than new services, it's about embedding
GenIP at the center of the commercialisation decision making process of
research organizations and corporates.

With the Invention Evaluator report as the trusted entry point, every new
product line we launch is designed to build directly on that foundation. This
correlation ensures continuity for clients while multiplying the value of each
engagement.

This evolution not only drives recurring, SaaS-style revenues and higher
margins but also deepens our data advantage and strengthens GenIP's long-term
market position. It reflects our deliberate strategy to move from being a
service provider to becoming the platform of choice for universities,
corporates, and investors shaping the future of innovation."

 

 

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                                                 Via Redchurch Communications

 Melissa Cruz, CEO

 Beaumont Cornish Limited (Nominated Adviser)                              Tel:  +44 (0) 20 7628 3396

 Roland Cornish / Asia Szusciak / Andrew Price

 Novum Securities Limited (Broker)                                         Tel: +44 (0)20 7399 9425

 Jon Belliss                                                               JBelliss@novumsecurities.com

 Redchurch Communications (Financial PR)                                   genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated
Adviser and is authorised and regulated by the FCA. Beaumont Cornish's
responsibilities as the Company's Nominated Adviser, including a
responsibility to advise and guide the Company on its responsibilities under
the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed
solely to the London Stock Exchange. Beaumont Cornish is not acting for and
will not be responsible to any other persons for providing protections
afforded to customers of Beaumont Cornish nor for advising them in relation to
the proposed arrangements described in this announcement or any matter
referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation consultancy at the intersection of generative AI
and innovation strategy. We empower corporates, venture funds, and research
institutions to evaluate, commercialise, and scale breakthrough technologies.
By combining proprietary GenAI algorithms with expert human analysis, GenIP
delivers decision-grade insights and talent solutions that accelerate
innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

 Service                               Description                                                                   Value Proposition
 Invention Evaluator                   AI-powered market intelligence reports assessing the commercial potential of  Enables faster, evidence-based decisions on R&D prioritisation,
                                       emerging technologies                                                         investment, and IP strategy
 Talent and Executive Search Services  Executive search platform using machine learning and NLP to match             De-risks scaling by aligning technical vision with proven executive capability
                                       innovation-driven organisations with commercialisation-ready leadership

 

Together, these services form a unified GenAI-enabled platform for innovation
triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for
innovation commercialisation. Our strategy is anchored in three growth
pillars:

 

●     Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach
to corporates, VCs, and research institutions, supported by strategic
marketing and digital engagement.

●     Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both
service lines-unlocking new use cases and customer segments.

●     Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated
market traction to broaden our offering and accelerate growth.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

-ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDLLMBTMTTTBMA